West Coast Medical Labs INC
West Coast Medical Labs INC was paid $3.36M by Medicaid between Dec 2022 and Nov 2024, across 8 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 59% of everything it billed.
33Billing provider infoWEST COAST MEDICAL LABS INC
MANTECA, CA 95336
MANTECA, CA 95336
33aNPI1073272613assigned 12/10/2021
33bProvider typeSpecialist
28Total paid$3.36M
24GClaims32,925
24DCodes billed8
24AFirst – last monthDec 2022 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#71 of 1,230
Median peer was paid$51K
This provider vs. median65×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 140 | $264.84 | |
| 2023 | 8,376 | $20K | |
| 2024incomplete | 24,409 | $3.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 59% | 19,225 | 7,011 | $1.97M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 34% | 4,095 | 4,046 | $1.14M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.8% | 3,740 | 1,781 | $162K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 499 | 301 | $71K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,111 | 611 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,235 | 651 | $3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,225 | 710 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 795 | 476 | $523.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOHAMMED, ABDUL (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Clarity Testing Services | Arlington Heights, IL | $353K |
| Spectrum Lab Corp | Niles, IL | $45K |
| FZ Medical Group INC | Des Plaines, IL | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.